CN101632820A - Intestinal obstruction removal pill - Google Patents
Intestinal obstruction removal pill Download PDFInfo
- Publication number
- CN101632820A CN101632820A CN200810133750A CN200810133750A CN101632820A CN 101632820 A CN101632820 A CN 101632820A CN 200810133750 A CN200810133750 A CN 200810133750A CN 200810133750 A CN200810133750 A CN 200810133750A CN 101632820 A CN101632820 A CN 101632820A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- rhizoma
- vinegar
- intestinal obstruction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an intestinal obstruction removal pill, which comprises the following bulk medicaments: vinegar baked radix bupleuri, vinegar baked rhizoma cyperi, radix curcumae, tangerine seeds, semen litchi, seaweeds, prunella, rhizoma ligustici wallichii, prepared rhizome of rehmannia, angelica, red paeonia, leech, rhizoma sparganii, zedoary, cassia twig, radix astragali, tuckahoe, radix codonopsitis, and honey-fried licorice root. The intestinal obstruction removal pill has the advantages of the effects of promoting blood circulation by removing blood stasis, soothing the liver and promoting the circulation of qi, reducing phlegm and resolving masses, and supplementing qi and nourishing yin, and can effectively treat hyperplasia of mammary glands, oophoritic cyst and hysteromyoma.
Description
Technical field:
The present invention relates to intestinal obstruction removal pill, belong to the field of Chinese medicines.
Background technology:
Cyclomastopathy (hyperplasia of mammary gland) is a disease a kind of and due to the endocrine dysfunction.It is relevant with endocrine disturbance or Nervous and Mental Factors that the cause of disease is thought more.Estrogen promotes lactiferous ducts to reach connective tissue growth on every side, and Progesterone promotes the development of lobule and acinus.Inharmonious between the too high and Progesterone hyposecretion of estrogen or the two kinds of hormones, then cause breast duct epithelium and fibrous tissue hypertrophy in various degree.Tu Chu symptom is a mastalgia clinically, often is intermittence or dispersivity dull pain, in through preceding sx.
Hysteromyoma is modal female sex organs benign tumor.Hysteromyoma and cyclomastopathy all are more common in middle-aged women, and typical hysteromyoma is a substantial spherical lump, smooth surface or also have concavo-convex.The tangent plane helical form strain line that is white in color, little band injustice.Because the sickness rate height (period of duration women sickness rate is about 25%) of hysteromyoma, and also bigger to the harm of women's health, bring some shades can for women's daily life.As the conventional therapy approach, the doctor trained in Western medicine and the traditional Chinese medical science are treated hysteromyoma in different ways.
Cyclomastopathy is all relevant with the female incretion system with hysteromyoma, the healthy of women in serious threat, also do not have a kind of medicine to have therapeutical effect simultaneously at present to these two kinds of diseases, thus a lot of medical research personnel studying a kind of at the female incretion system uncomfortable have more medicine targetedly.
Theoretical foundation: cyclomastopathy belongs to " nodules of the breast " category of the traditional Chinese medical science, " surgeon's complete works. newborn painful abdominal mass door master opinion " says: " nodules of the breast ... how by worry impairing spleen; excessive anger impairing the liver, pent-up form also ", according to above-mentioned argumentation as can be known the main pathogenesis of primary disease be because stagnation of QI due to depression of the liver, insufficiency of the spleen disease is with fixed attention.Regulating qi to disperse stagnation, supplementing QI and nourishing YIN are worked as in treatment.Ovarian cyst belongs to the category of the traditional Chinese medical science " lump in the abdomen ", " gathering ", " a Ling Shu Miraculous Pivot or Divine Axis water vein piece of writing " say " stony mass of uterus is born among the born of the same parents, pathogenic cold invasion in the cervical orifice of the uterus, cervical orifice of uterus obturation; gas must not lead to, stagnant blood is when rushing down, blood does not end to stay; day big with benefit, shape is as cherishing son, irregular menstrual cycle ... ".According to above argumentation as can be known the main pathogenesis of primary disease be because cold coagulation, the stagnation of QI is due to the blood stasis.Strengthening vital QI to eliminate pathogenic factors is worked as in treatment, sets upright when the invigorating the spleen and replenishing QI yin nourishing, gets rid of evils and answers cold expelling circulation of qi promoting, blood circulation promoting and blood stasis dispelling.
Summary of the invention:
The object of the present invention is to provide a kind of medicine-intestinal obstruction removal pill that can effectively treat cyclomastopathy, ovarian cyst and hysteromyoma.
Solution of the present invention is based on motherland medical science is based on understanding and the Therapeutic Principle of motherland to medical science cyclomastopathy, ovarian cyst and Uterine myomas mechanism, cyclomastopathy belongs to the traditional Chinese medical science " nodules of the breast " category, " surgeon's complete works. newborn painful abdominal mass door master opinion " say: " nodules of the breast ... how by worry impairing spleen; excessive anger impairing the liver, pent-up form also ", according to above-mentioned argumentation as can be known the main pathogenesis of primary disease be because stagnation of QI due to depression of the liver, insufficiency of the spleen disease is coagulated.Regulating qi to disperse stagnation, supplementing QI and nourishing YIN are worked as in treatment.Ovarian cyst belongs to the category of the traditional Chinese medical science " lump in the abdomen ", " gathering ", " a Ling Shu Miraculous Pivot or Divine Axis water vein piece of writing " say " stony mass of uterus is born among the born of the same parents, pathogenic cold invasion in the cervical orifice of the uterus, cervical orifice of uterus obturation; gas must not lead to, stagnant blood is when rushing down, blood does not end to stay; day big with benefit, shape is as cherishing son, irregular menstrual cycle ... ".According to above argumentation as can be known the main pathogenesis of primary disease be because cold coagulation, the stagnation of QI is due to the blood stasis.Strengthening vital QI to eliminate pathogenic factors is worked as in treatment, sets upright when the invigorating the spleen and replenishing QI yin nourishing, gets rid of evils and answers cold expelling circulation of qi promoting, blood circulation promoting and blood stasis dispelling.
Radix Bupleuri (processed with vinegar), Radix Curcumae, Sargassum, Spica Prunellae, Semen Citri Reticulatae, Semen Litchi, Rhizoma Cyperi (processed with vinegar) soothing liver-QI for relieving depression in the side, the hard masses softening and resolving circulation of qi promoting; Rhizoma Chuanxiong, Radix Angelicae Sinensis, rhizoma sparganic, Rhizoma Curcumae, Radix Paeoniae Rubra, Hirudo blood circulation promoting and blood stasis dispelling, the removing blood stasis eliminating stagnation; Invigorating blood circulation of Ramulus Cinnamomi warming YANG to expel cold stagnates; Radix Codonopsis, Radix Glycyrrhizae Preparata, the sharp phlegm-damp of Poria invigorating the spleen and benefiting QI, Radix Rehmanniae Preparata yin nourishing taste essence is enriched blood.All medicines share, and play blood circulation promoting and blood stasis dispelling altogether, soothing liver-QI circulation of qi promoting, dissipating phlegm and resolving masses.The effect of supplementing QI and nourishing YIN.
Intestinal obstruction removal pill includes following bulk drugs and forms: Radix Bupleuri (processed with vinegar) 10-20 part, Rhizoma Cyperi (processed with vinegar) 10-20 part, Radix Curcumae 10-20 part, Semen Citri Reticulatae 10-30 part, Semen Litchi 10-30 part, Sargassum 20-40 part, Spica Prunellae 20-40 part, Rhizoma Chuanxiong 10-30 part, Radix Rehmanniae Preparata 10-30 part, Radix Angelicae Sinensis 10-20 part, Radix Paeoniae Rubra 10-30 part, Hirudo 10-30 part, rhizoma sparganic 5-15 part, Rhizoma Curcumae 5-15 part, Ramulus Cinnamomi 10-20 part, Radix Astragali 20-40 part, Poria 10-30 part, Radix Codonopsis 10-30 part, Radix Glycyrrhizae Preparata 10-20 part.
Intestinal obstruction removal pill, its optimization formula is: the weight proportion of each raw material is 15 parts of Radix Bupleuri (processed with vinegar), 15 parts of Rhizoma Cyperi (processed with vinegar), 15 parts of Radix Curcumaes, 20 parts of Semen Citri Reticulataes, 20 parts of Semen Litchis, 30 parts of Sargassums, 30 parts of Spica Prunellaes, 20 parts of Rhizoma Chuanxiongs, 20 parts in Radix Rehmanniae Preparata, 15 parts of Radix Angelicae Sinensis, 20 parts of Radix Paeoniae Rubra, 20 parts of Hirudos, 10 parts of rhizoma sparganic, 10 parts of Rhizoma Curcumae, 15 parts of Ramulus Cinnamomi, 30 parts of the Radixs Astragali, 20 parts in Poria, 20 parts of Radix Codonopsis, 15 parts of Radix Glycyrrhizae Preparatas.
Described medicine can be made close ball, the watered pill, capsule, tablet.
The invention has the advantages that: the effect of blood circulation promoting and blood stasis dispelling, soothing the liver circulation of qi promoting, dissipating phlegm and resolving masses, supplementing QI and nourishing YIN, can effectively treat cyclomastopathy, ovarian cyst and hysteromyoma.
The specific embodiment:
Embodiment 1: intestinal obstruction removal pill includes following crude drug and forms: Radix Bupleuri (processed with vinegar) 100g, Rhizoma Cyperi (processed with vinegar) 100g, Radix Curcumae 100g, Semen Citri Reticulatae 100g, Semen Litchi 100g, Sargassum 200g, Spica Prunellae 200g, Rhizoma Chuanxiong 100g, Radix Rehmanniae Preparata 100g, Radix Angelicae Sinensis 100g, Radix Paeoniae Rubra 100g, Hirudo 100g, rhizoma sparganic 50g, Rhizoma Curcumae 50g, Ramulus Cinnamomi 100g, Radix Astragali 200g, Poria 100g, Radix Codonopsis 100g, Radix Glycyrrhizae Preparata 100g.This medicine can be made into honeyed pill, takes twice every day, takes 9 grams at every turn.
Embodiment 2: intestinal obstruction removal pill includes following crude drug: Radix Bupleuri (processed with vinegar) 200g, Rhizoma Cyperi (processed with vinegar) 200g, Radix Curcumae 200g, Semen Citri Reticulatae 300g, Semen Litchi 300g, Sargassum 400g, Spica Prunellae 400g, Rhizoma Chuanxiong 300g, Radix Rehmanniae Preparata 300g, Radix Angelicae Sinensis 200g, Radix Paeoniae Rubra 300g, Hirudo 300g, rhizoma sparganic 150g, Rhizoma Curcumae 150g, Ramulus Cinnamomi 200g, Radix Astragali 400g, Poria 300g, Radix Codonopsis 300g, Radix Glycyrrhizae Preparata 200g.This medicine can be made into the watered pill, takes twice every day, takes 9 grams at every turn.
Embodiment 3: intestinal obstruction removal pill includes crude drug and forms: Radix Bupleuri (processed with vinegar) 15g, Rhizoma Cyperi (processed with vinegar) 15g, Radix Curcumae 15g, Semen Citri Reticulatae 20g, Semen Litchi 20g, Sargassum 30g, Spica Prunellae 30g, Rhizoma Chuanxiong 20g, Radix Rehmanniae Preparata 20g, Radix Angelicae Sinensis 15g, Radix Paeoniae Rubra 20g, Hirudo 20g, rhizoma sparganic 10g, Rhizoma Curcumae 10g, Ramulus Cinnamomi 15g, Radix Astragali 30g, Poria 20g, Radix Codonopsis 20g, Radix Glycyrrhizae Preparata 15g.This medicine can be made into the watered pill, takes twice every day, takes 9 grams at every turn.
Embodiment 4: the prepared medicine of embodiment of the invention 1-3 is to the experiment of treatment rat uterus muscular tumor
One, observes the influence of medicine of the present invention, illustrate its mechanism of action rat uterus muscular tumor animal model
Induce rat to set up the uterine fibroid disease varying model with exogenous hormones, observe medicine of the present invention to superoxide dismutase in the influence of the tissue morphology in uterus and the serum (superoxidedismutase, SOD), the variation of malonaldehyde (MDA) content; Adopt Use immunohistochemistrySP SP detect the rat uterus muscular tumor organize estrogen receptor (estrone receptor, ER), progesterone receptor (progesterone receptor, expression PR).
Compare with model group, medication therapy groups of the present invention can suppress hysteromyoma hamartoplasia, and the active rising of SOD, MDA content reduce in the serum; The expression of ER, PR obviously weaken (P＜0.01, PC).
Conclusion: medicine of the present invention has therapeutical effect to hysteromyoma, its mechanism of action and the expression that suppresses ER, PR, and the content of reduction MDA, the activity that increases SOD is relevant.
The result
The histological observation result
Normal control group uterus shape structure is normal, and the uterus body of gland does not have the hypertrophy phenomenon;
Body of gland obvious hypertrophy in model group uterus, has cavity at endometrial cell irregular arrangement, swelling;
Each group of Drug therapy of the present invention does not all have glandular hyperplasia and other abnormal phenomenas; The normal heavy dose of medication therapy groups rat uterus organizational structure of the present invention of low dose of medication therapy groups rat uterus organizational structure of the present invention normal (HE, * 400)
Immunohistochemical staining and photodensitometry result
The immunohistochemical SP method coloration result shows that PR, ER albumen all have expression in the endochylema of internal film tissue, inner membrance undertissue and the muscle layer tissue in uterus, and visible light yellow PR, ER protein expression present the weak positive in the normal group uterine cancer cell cytoplasm.Visible filemot PR, ER protein expression are strong positive in the model group uterine cancer cell cytoplasm.The proteic expression of medication therapy groups PR of the present invention, ER weakens, and is tending towards normal substantially.ZD801 graphical analysis result shows between other each group and model group all significant difference (P＜0.01).
Table 1 medicine of the present invention is to rat uterus ER, PR optical density result's influence
Compare with model group, each organizes equal P＜0.01
Serum superoxide dismutases (SOD), mda content (MDA) measurement result
Model group compares with the normal control group that SOD is active obviously to descend (P＜0.01), and the activity of heavy dose of medication therapy groups SOD of the present invention and model group relatively have obviously and increase (P＜0.01); Model group MDA content obviously increases, and between heavy dose of, normal group significant differences is arranged
(P＜0.01), and significant difference (P＜0.05), (table 2) are arranged between small dose group.
Table 2 medicine of the present invention is to the influence of superoxide dismutase, mda content
Compare * * P＜0.01 with model group; * P＜0.05;
Discuss
Hysteromyoma is the common benign tumor of gynecological.Good sending out in 30～50 years old young women.Belong to the medical science Zhong “ of motherland WEIJIA " category.The pathogenic factors of hysteromyoma, doctor trained in Western medicine are thought to stimulate relevant with long-term a large amount of estrogen that continue.The traditional Chinese medical science thinks that this is sick because feelings will is hindered, and the internal organs discord is due to stopping in the blood stasis, clinical this is demonstrate,proved existing QI and blood and is detained, uterus silt resistance is real, insufficiency of vital energy and blood is arranged, the void of many visceral dysfunctions again, a large amount of clinical experimental research show, dialectical the executing of utilization Chinese medicine controlled, and can obviously improve symptom, even muscular tumor is dissipated, do not influence fertility again, its effect unique is arranged.But the report about the mechanism aspect of treatment by Chinese herbs hysteromyoma is rare.Exogenous hormones is used in this experiment, has successfully set up the animal model of rat uterus muscular tumor, for treatment and the pathogeny of using the zooscopy hysteromyoma provides prerequisite.
This experimental result shows that MDA is active in the model group rises greatly, and SOD is active to descend; The activity of medication therapy groups MDA of the present invention and SOD is similar to the normal control group, with model group significant difference is arranged relatively, and the participation that oxygen-derived free radicals is arranged in the Drug therapy hysteromyoma process of the present invention is described.Therefore, antioxidant radical damage and anti-peroxidation damage are one of mechanism of Drug therapy hysteromyoma of the present invention.
Two, the outgrowth experimentation of Drug therapy rat mammary gland of the present invention
Observe the influence of medicine of the present invention, illustrate its mechanism of action rat mammary gland hypertrophy (Mammary Gland Hyperplasia:MGH) animal model.
Method: induce rat to set up the cyclomastopathy disease model with exogenous hormones, observe superoxide dismutase in the influence of its tissue morphology, good size and spaced farapart and the serum (superoxide dismutase, SOD) changes of contents of active and malonaldehyde (MDA) to mammary gland; Adopt Use immunohistochemistrySP SP detect rat mammary gland organize estrogen receptor (estronereceptor, ER), progesterone receptor (progesterone receptor, expression PR).The result compares with model group, and medication therapy groups of the present invention can suppress mammoplasia, and with the high dose group most pronounced effects, the active rising of SOD (P＜0.01) in the serum, MDA content reduce (P＜0.05); The expression of ER, PR obviously weakens, (P＜0.01, P＜0.05).The mechanism of conclusion Drug therapy cyclomastopathy of the present invention may with the expression of its inhibition ER, PR, reducing MDA content, to increase the activity of SOD relevant.
Cyclomastopathy is the modal disease of mammary glands in women, thinks that its morbidity is relevant with the endocrine disturbance more.Its clinical main performance is mastalgia and lump in breast, and painful area is based on the lump in breast place.Medicine of the present invention is a kind of new drug for the treatment of cyclomastopathy, in order to verify its curative effect, adopts external source estrogen and progestogen to induce rat, sets up the outgrowth animal model of rat mammary gland, observes it to the outgrowth therapeutic effect of rat mammary gland, and illustrates its mechanism of action.
The result
The mammary gland tissue observed result
The nipple of model group rat obviously increases, and compares with normal negative control group, and difference has significance meaning (P＜0.05); The papilla diameter that rat is respectively organized in medication has the trend that obviously diminishes, and relatively, difference all has significance meaning (P＜0.05 or P＜0.01) between model group and low dose group, high dose group, RUPIXIAO positive controls; Compare there was no significant difference (p＞0.05) (table 1) between low dose group and normal negative control group.
Normal negative control group rat breast is less, and lobule is not obvious, and acinus is less, and the gland conduit does not have expansion, visible more connective tissue and fatty tissue (Fig. 1); The model group breast obviously increases, and body of gland is the diffuse type hypertrophy, and acinus increases, and lobule is obvious, and alveolar lumen is obviously expanded, and the ductal epithelium arrangement disorder has a large amount of pink colour secretions (Fig. 2) in the conduit; RUPIXIAO positive controls, medicine of the present invention middle and high dosage group lobule and acinus obviously reduce, and be approaching normal, wherein high dose group pathological change minimum.
Table 3 is respectively organized rat height of nipples and diameter variation (X ± S)
1. compare P＜0.05 with model group; 2. compare P＜0.01 with model group;
Immunohistochemical staining and photodensitometry result:
Visible light yellow ER, PR protein expression present the weak positive in the normal group mammary glandular cell slurry.High dose group the two expression and the normal control category seemingly.Model group is visible yellowish-brown ER, PR protein expression in mammary glandular cell slurry and glandular tube endochylema, is strong positive.The expression and the model group of low dose group are approaching, are strong positive.The RUPIXIAO positive controls compares with normal negative control group, and the two is expressed enhancing slightly; The ZD801 graphical analysis is the result show, model group and low dose group differences do not have significance meaning (P＞0.05), and relatively, difference all has significance meaning (P＜0.01 between other each group and model group; P＜0.05) (table 4)
Table 4 medicine of the present invention is to rat mammary gland ER, PR optical density result's influence
1. compare P＜0.05 with model group; 2. compare P＜0.01 with model group; 3. compare P＞0.05 with model group;
Serum superoxide dismutases (SOD) is active, malonaldehyde (MDA) assay result
Model group SOD is active obviously to descend, each administration group, and along with drug dose increases, SOD's is active on the rise.Wherein, normal group and model group comparing difference have significance meaning (P＜0.01), and comparing difference does not have significance meaning (P＞0.05) between other each groups and model group; Model group MDA content obviously increases, and with low dosage, normal group differences highly significant meaning (P＜0.01) is arranged, and with the high dose group differences significance meaning (P＜0.05) is arranged, and does not then have significance meaning (P＞0.05 with the positive control group difference; See Table 5).
Table 5 medicine of the present invention is to the influence of superoxide dismutase, mda content
1. compare P＜0.05 with model group; 2. compare P＜0.01 with model group; 3. compare P＞0.05 with model group;
Discuss:
Mammary gland is the important target organ of hypothalamus one hypophysis, one hypothalamic pituitary ovarium axis hormone, and the normal growth of mammary gland is grown the influence that directly is subjected to estrogen.The imbalance of the generation of bibliographical information cyclomastopathy and reproductive endocrine function is relevant, mainly be in the body the low and excessive long term of estrogen secretion of progesterone level in the result of mammary gland tissue.This principle of this experimental basis uses exogenous estrogen and progestogen to induce rat, causes rat mammary gland hamartoplasia, and cyclomastopathy all appears in experimental group as a result, and the normal control group is not found cyclomastopathy, and the manufacture method that this kind model is described is feasible.
Cyclomastopathy belongs to the traditional Chinese medical science " as addiction " category, and main pathogeny is owing to stagnation of QI due to depression of the liver, and insufficiency of the spleen disease is coagulated; Often injure gas the moon owing to crossing with the product of hot dry circulation of qi promoting clinically, also can form the situation of simulataneous insufficiency and excessive.Method of treatment is when invigorating the spleen and replenishing QI yin nourishing, promoting the circulation of QI and reducing phlegm.In the medicine of the present invention, use Radix Angelicae Sinensis, Rhizoma Chuanxiong, Squama Manis, rhizoma sparganic, Rhizoma Curcumae, Radix Salviae Miltiorrhizae with the blood circulation promoting and blood stasis dispelling circulation of qi promoting: to use Radix Curcumae, Rhizoma Corydalis with soothing liver-QI for relieving depression and blood circulation promoting and blood stasis dispelling; Use Radix Bupleuri, Sargassum, Rhizoma Cyperi, Spica Prunellae, Fructus Citri tangerinae are examined with the diffusing hard eliminating stagnation of dispersing the stagnated live-QI to relieve the stagnation of QI and reduce phlegm; Ramulus Cinnamomi warming YANG to expel cold wherein, invigorating blood circulation stagnates; Radix Codonopsis, Radix Glycyrrhizae, Semen Coicis, Poria are with the sharp phlegm-damp of invigorating the spleen and benefiting QI; Radix Rehmanniae Preparata is grown smart with yin nourishing and is enriched blood; Said medicine is shared to play the effect of blood circulation promoting and blood stasis dispelling, soothing the liver circulation of qi promoting, dissipating phlegm and resolving masses, supplementing QI and nourishing YIN altogether.
This result of study shows, compare with normal negative control group, the nipple of model group rat obviously increases, and pathological section shows that breast obviously increases, and body of gland is the diffuse type hypertrophy, acinus increases, lobule is obvious, and alveolar lumen is obviously expanded, the ductal epithelium arrangement disorder, a large amount of pink colour secretions is arranged, with results reported basically identicals such as Huang Yueling in the conduit.The papilla diameter that rat is respectively organized in medication has the trend that obviously diminishes.The structure observation result shows that medicine of the present invention middle and high dosage group lobule and acinus obviously reduce, and is approaching normal, wherein high dose group pathological change minimum.Illustrate that medicine of the present invention can effectively suppress the hypertrophy of rat mammary gland tissue.
Model group mammary gland tissue EP albumen and RP protein expression are strong positive, the pathological change of hamartoplasia is also very obvious, and the two expression of negative control group is the weak positive, the outgrowth pathological change of inorganization, middle and high the two expression intensity of dosage group of medicine of the present invention is consistent substantially with the change of hamartoplasia.Illustrate that EP albumen and RP albumen play important effect in the outgrowth morbidity of rat mammary gland.
Three, the experimentation of Drug therapy rat ovary cyst of the present invention
Ovarian cyst is the common disease of gynecological, can occur in any age.We used intestinal obstruction removal pill treatment ovarian cyst in 2005-2007, and used the colorful ultrasonic diagnostic apparatus, observe the curative effect, and effect is satisfied.This group of physical data patient 122 examples, 22～55 years old age, average 34 years old; Result: cure 85 examples, 22 examples that take a turn for the better, invalid 15 examples, total effective rate 87.7%.
Claims (3)
1, intestinal obstruction removal pill, it is characterized in that it includes following bulk drugs and forms: Radix Bupleuri (processed with vinegar) 10-20 part, Rhizoma Cyperi (processed with vinegar) 10-20 part, Radix Curcumae 10-20 part, Semen Citri Reticulatae 10-30 part, Semen Litchi 10-30 part, Sargassum 20-40 part, Spica Prunellae 20-40 part, Rhizoma Chuanxiong 10-30 part, Radix Rehmanniae Preparata 10-30 part, Radix Angelicae Sinensis 10-20 part, Radix Paeoniae Rubra 10-30 part, Hirudo 10-30 part, rhizoma sparganic 5-15 part, Rhizoma Curcumae 5-15 part, Ramulus Cinnamomi 10-20 part, Radix Astragali 20-40 part, Poria 10-30 part, Radix Codonopsis 10-30 part, Radix Glycyrrhizae Preparata 10-20 part.
2, intestinal obstruction removal pill according to claim 1, it is characterized in that wherein the weight proportion of each raw material is 15 parts of Radix Bupleuri (processed with vinegar), 15 parts of Rhizoma Cyperi (processed with vinegar), 15 parts of Radix Curcumaes, 20 parts of Semen Citri Reticulataes, 20 parts of Semen Litchis, 30 parts of Sargassums, 30 parts of Spica Prunellaes, 20 parts of Rhizoma Chuanxiongs, 20 parts in Radix Rehmanniae Preparata, 15 parts of Radix Angelicae Sinensis, 20 parts of Radix Paeoniae Rubra, 20 parts of Hirudos, 10 parts of rhizoma sparganic, 10 parts of Rhizoma Curcumae, 15 parts of Ramulus Cinnamomi, 30 parts of the Radixs Astragali, 20 parts in Poria, 20 parts of Radix Codonopsis, 15 parts of Radix Glycyrrhizae Preparatas.
3, intestinal obstruction removal pill according to claim 1 and 2 is characterized in that, described medicine can be made close ball, the watered pill, capsule, tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101337500A CN101632820B (en) | 2008-07-24 | 2008-07-24 | Intestinal obstruction removal pill |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101337500A CN101632820B (en) | 2008-07-24 | 2008-07-24 | Intestinal obstruction removal pill |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101632820A true CN101632820A (en) | 2010-01-27 |
| CN101632820B CN101632820B (en) | 2011-11-23 |
Family
ID=41592255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101337500A Expired - Fee Related CN101632820B (en) | 2008-07-24 | 2008-07-24 | Intestinal obstruction removal pill |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101632820B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797323A (en) * | 2010-04-02 | 2010-08-11 | 吕红权 | Chinese medicinal composition for treating mammary hyperplasia |
| CN102247581A (en) * | 2011-08-18 | 2011-11-23 | 王思曾 | Medicament for treating myoma of uterus |
| CN102908603A (en) * | 2012-10-30 | 2013-02-06 | 王凤 | Chinese medicament for treating hyperplasia of mammary glands |
| CN103212047A (en) * | 2013-04-22 | 2013-07-24 | 窦子云 | Traditional Chinese medicine composition for treating hysteromyoma and ovarian cysts |
| CN103356969A (en) * | 2013-07-26 | 2013-10-23 | 黄淑娟 | Traditional Chinese medicine composition for treating hysteromyoma |
| CN105031545A (en) * | 2015-08-28 | 2015-11-11 | 咸阳夏华中医乳腺病研究所 | Orally taken traditional Chinese medicine for treating hyperplasia of mammary glands |
| CN105233165A (en) * | 2015-11-05 | 2016-01-13 | 孙绪连 | Traditional Chinese medicine for treating ovarian cyst |
| CN105343714A (en) * | 2015-12-11 | 2016-02-24 | 靖州苗族侗族自治县科技推广中心 | Health care tea for preventing and treating myoma of uterus and ovarian cyst and preparing method thereof |
| CN113144148A (en) * | 2021-05-20 | 2021-07-23 | 漳州卫生职业学院 | Oral and external traditional Chinese medicine for treating liver depression, phlegm dampness and blood stasis type hyperplasia of mammary glands and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1217680C (en) * | 2002-04-08 | 2005-09-07 | 马菲亚 | Repellent mixture for department of gynecology |
| CN1255180C (en) * | 2003-11-09 | 2006-05-10 | 黄双元 | Chinese patent drug for treating female ovarian cyst and its preparation |
| CN100376286C (en) * | 2006-04-10 | 2008-03-26 | 庞来祥 | Medicinal composition for treating chronic pelvic inflammatory disease, prepn. method and quality control method therefor |
-
2008
- 2008-07-24 CN CN2008101337500A patent/CN101632820B/en not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797323A (en) * | 2010-04-02 | 2010-08-11 | 吕红权 | Chinese medicinal composition for treating mammary hyperplasia |
| CN102247581A (en) * | 2011-08-18 | 2011-11-23 | 王思曾 | Medicament for treating myoma of uterus |
| CN102247581B (en) * | 2011-08-18 | 2013-03-27 | 王思曾 | Medicament for treating myoma of uterus |
| CN102908603A (en) * | 2012-10-30 | 2013-02-06 | 王凤 | Chinese medicament for treating hyperplasia of mammary glands |
| CN102908603B (en) * | 2012-10-30 | 2014-06-18 | 王凤 | Chinese medicament for treating hyperplasia of mammary glands |
| CN103212047A (en) * | 2013-04-22 | 2013-07-24 | 窦子云 | Traditional Chinese medicine composition for treating hysteromyoma and ovarian cysts |
| CN103356969A (en) * | 2013-07-26 | 2013-10-23 | 黄淑娟 | Traditional Chinese medicine composition for treating hysteromyoma |
| CN105031545A (en) * | 2015-08-28 | 2015-11-11 | 咸阳夏华中医乳腺病研究所 | Orally taken traditional Chinese medicine for treating hyperplasia of mammary glands |
| CN105031545B (en) * | 2015-08-28 | 2018-09-11 | 咸阳夏华中医乳腺病研究所 | A kind of traditional Chinese medicine for oral administration for treating the proliferation of mammary gland |
| CN105233165A (en) * | 2015-11-05 | 2016-01-13 | 孙绪连 | Traditional Chinese medicine for treating ovarian cyst |
| CN105343714A (en) * | 2015-12-11 | 2016-02-24 | 靖州苗族侗族自治县科技推广中心 | Health care tea for preventing and treating myoma of uterus and ovarian cyst and preparing method thereof |
| CN113144148A (en) * | 2021-05-20 | 2021-07-23 | 漳州卫生职业学院 | Oral and external traditional Chinese medicine for treating liver depression, phlegm dampness and blood stasis type hyperplasia of mammary glands and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101632820B (en) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632820B (en) | Intestinal obstruction removal pill | |
| CN102940853B (en) | Navel paste for treating mammary gland hyperplasia diseases | |
| CN105106852A (en) | Traditional Chinese medicine preparation for treating hyperplasia of mammary glands and breast cancer | |
| CN1289137C (en) | Medicine for treating mammary gland proliferation, its preparation method and application | |
| CN100493569C (en) | Medicament for preventing and treating benign hyperplasia of mammary glands for women and preparation process thereof | |
| CN102988543B (en) | Traditional Chinese medicine for treating hyperplasia of mammary glands and preparation method of traditional Chinese medicine | |
| CN103893464B (en) | Traditional Chinese medicine preparation used for adjusting menstrual period and promoting pregnancy | |
| CN103446500B (en) | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction | |
| CN104740536A (en) | Pharmaceutical composition for treating endometriosis (EMT) and adenomyosis (AM) and preparation method and use thereof | |
| CN101642519B (en) | Chinese patent medicine for treating mammary gland hyperplasia and preparation technique thereof | |
| CN101259214B (en) | Medicine for treating hyperplasia of mammary glands | |
| CN103705846A (en) | Traditional Chinese medicine preparation for treating ovarian cyst | |
| CN1322894C (en) | Chinese medicine for treating nipple discharge | |
| CN105853930A (en) | Traditional Chinese medicine composition for treating depression | |
| CN105031545B (en) | A kind of traditional Chinese medicine for oral administration for treating the proliferation of mammary gland | |
| CN111135270A (en) | A Chinese medicinal composition for treating female hyperplasia of mammary glands due to stagnation of qi and stagnation of liver-qi and stagnation of phlegm and blood stasis | |
| CN109432364A (en) | The female Chinese medicine composition of ginseng stilbene benefit and the preparation method and application thereof for Recovery | |
| CN103536745A (en) | Traditional Chinese medicinal watered pills for treating hyperplasia of mammary glands | |
| CN102406811A (en) | Traditional Chinese medicine composition for treating ovarian cyst | |
| CN101721503A (en) | Traditional Chinese medicine preparation for treating sterility and infertility of men and women | |
| CN106552240A (en) | A kind of Chinese medicinal ointment for treating qi depression to blood stasis phlegm stagnation type cyclomastopathy | |
| CN104721737A (en) | External preparation for hyperplasia of mammary glands | |
| CN104524344A (en) | Traditional Chinese medicine preparation for treating chloasma | |
| CN102813858A (en) | Traditional Chinese medicine for treating postpartum flooding by tonifying middle-jiao and vital energy | |
| CN1515307A (en) | Medicine for curing hysteromyoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111123 Termination date: 20140724 |
|
| EXPY | Termination of patent right or utility model |